CD8A and neoplasm: To our knowledge, this study uniquely demonstrated that a peptide-pulsed semiallogeneic DC vaccine can enhance the direct CD8+ CTL response by presenting tumor-specific peptides on syngeneic MHC class I molecules, while also generating robust allospecific CD4+ T cell help via mutant MHC class II molecules.